• Home
  • Corporate Symposia

Corporate Symposia

AC Forum is happy to present the 2019 Corporate Symposia Program. Please note the following:

  • Each event is planned independently of the AC Forum program committee and AC Forum does not endorse the programming content of any event.
  • You must be a AC Forum registrant in order to attend a corporate symposium. There is no cost to attend any of the corporate symposia.
  • All symposia occur during a meal and food will be provided.
  • If a pre-registration link is not provided, all admittance will be on a first-come, first-served basis.

Please find the corporate symposia schedule below.

Thursday, April 11: Lunch Sessions

Clinical Trial Results Complemented by a Real-World Database Analysis of a Medicare Nonvalvular Atrial Fibrillation (NVAF) Population
12:30pm - 2:00pm
Great Hall 5
Sponsored by BMS/PFIZER


Advances in the Management of CAD/PAD: A New Treatment For Thrombotic Risk Reduction
12:30pm - 2:00pm
Great Hall 6

Program Description: Patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) are at risk for major cardiovascular events, including cardiovascular death, myocardial infarction, and stroke. Join us for a presentation describing a newly approved approach to reducing the risk of these events.

Speaker: Brett A. Sealove, MD, FACC, RPVI Monmouth Cardiology Associates, LLC Core Assistant Professor Seton Hall – Hackensack Meridian School of Medicine Eatontown, New Jersey

Sponsored by Janssen Pharmaceuticals, Inc.

Thursday, April 11: Evening Reception Session

How Evidence-Derived Clinical Decision Support within Electronic Health Records Can Improve Delivery of Optimized Anticoagulant Therapy: The Point of Care AC Decision Support Experience

Thursday, April 11
5:30pm - 6:30pm
Great Hall 5

Please pre-register to attend: PCDS AC Forum Symposium Registration Link

Program Description: Anticoagulant therapy such as warfarin or Direct Oral Anticoagulants is used by millions of Americans and are amongst the most likely to lead to serious adverse events leading to emergency department visits and hospitalizations. Evidence-based therapy mandated by national quality directives promotes a systematic approach to managing patients using dedicated anticoagulant management systems. Recently, a consensus statement from the EHR Task Force of the New York State Anticoagulation Coalition generated 78 recommended EHR features across 20 key discrete areas for necessary implementation into EHRs in order to deliver optimal AC care. These elements, along with new guidelines from the Joint Commission, include key decision support in the management and dosing of patients on warfarin and DOACs as well as the ability to have patient tracking and record keeping. The Point of Care AC Decision Support system has been built to incorporate all of these key features that are necessary to safely treat AC patients in the digital era of antithrombotic therapy. Key quality metric improvement, efficiency for various delivery models of AC care and workflows using the Point of Care AC Decision Support will be discussed.

Speaker: Alex C Spyropoulos, MD, FACP, FCCP, FRCPC
Professor of Medicine – The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Professor – The Center for Health Innovations and Outcomes Research, The Feinstein Institute for Medical Research, System Director – Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital

Sponsored by Point of Care Decision Support

Friday, April 12: Lunch Sessions

Reversal Of Specific Direct Oral Anticoagulants In Patients Experiencing Life-Threatening Bleeds
12:30pm - 2:00pm 
Great Hall 5 

Sponsored by Portola Pharmaceuticals


PT/INR Testing: Calibration, Correlation, Concordance

12:30pm - 2:00pm 
Great Hall 6 
Lunch will be provided to the first 100 attendees.

Program Description: Monitoring oral anticoagulation patients can be complex as frequent monitoring is required to minimize the risk of bleeding or thrombosis (clotting). The INR (International Normalized Ratio) was developed to standardize the tests used to monitor these patients, but falls shy of true standardization.

Speaker: Marcia L. Zucker, Ph.D., ZIVD, LLC will be joining us this year at AC Forum to share valuable information regarding the reasons behind the apparent lack of standardization, evaluating both lab to lab and lab to point-of-care (POC) variability. You will also uncover ways to mitigate the variability to ensure best patient care practices

During Marcia’s presentation, you will also learn about the history and evolution of PT/INR testing, calibration and its effects, why INR results between methods don't always match, and how to compare results.

Sponsored by Roche Diagnostics Corporation